Advertisement

Topics

International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019

20:00 EDT 16 May 2019 | Globe Newswire

CARLSBAD, Calif., May 17, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update announcing operating results for the three months ended March 31, 2019.

"In Q1 2019 we recently achieved a major milestone in the world's first approved human pluripotent stem cell-based clinical trial for the treatment of Parkinson's disease. We completed enrollment and treatment of all patients with our lead therapeutic product ISC-hpNSC® cells.  Based on the available data, we believe that the therapy is safe and well tolerated, meeting the primary endpoint of the phase 1 clinical trial. In connection with the conclusion of the treatment phase of the study, we anticipate the clinical trial-related expenses to significantly decrease," commented Andrey Semechkin, PhD., CEO and Co-Chairman of ISCO.

Q1 2019 Financial Highlights

  • Consolidated revenue for the first quarter of 2019 was $2.2 million, a decrease of 15% compared to the consolidated revenue of $2.6 million for the first quarter of 2018.
  • Combined operating income for the quarter ended March 31, 2019 from our two wholly owned revenue generating subsidiaries was $169,000, a decrease of 73% compared to $631,000 in the first quarter of 2018.
  • Net loss for ISCO was $906,000 for the first quarter of 2019 compared to a net loss of $830,000 million for the first quarter in 2018, an increase of 9 %. 

Recent Clinical Trial Highlights

  • ISCO completed subject enrollment in its phase 1 clinical trial of ISC-hpNSC® for the treatment of Parkinson's disease. The fourth subject of the third cohort, who was the twelfth and final subject of the phase 1 clinical study, was successfully transplanted with the highest dose of ISC-hpNSC® cells. 
  • Presented interim clinical results at the American Academy of Neurology annual meeting in Philadelphia, PA.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).

For more information, please visit http://internationalstemcell.com/ or contact:

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments and company achievements, expected clinical studies (including timing and results), anticipated protection from patents, and trends in clinical trial related expenses, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.


International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share data and par value)

  March 31,  December 31, 
  2019  2018 
Assets (Unaudited)     
Cash $615  $1,075 
Accounts receivable, net of allowance for doubtful accounts of $12  957   651 
Inventory, net  1,460   1,501 
Prepaid expenses and other current assets  480   543 
Total current assets  3,512   3,770 
Non-current inventory  792   805 
Property and equipment, net  652   469 
Intangible assets, net  2,700   2,674 
Right-of-use asset  933    
Deposits and other assets  74   78 
Total assets $8,663  $7,796 
Liabilities and Stockholders' Equity        
Accounts payable $806  $458 
Accrued liabilities  959   579 
Operating lease liability, current  294    
Related party payable  1,009   2,045 
Advances  250   250 
Fair value of warrant liability  1,148   1,745 
Total current liabilities  4,466   5,077 
Long-term deferred rent     182 
Operating lease liability, net of current portion  1,011    
Total liabilities  5,477   5,259 
Commitments and Contingencies        
Stockholders' Equity        
Series B Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized, 250,000
  issued and outstanding, with liquidation preferences of $415 and $411 at March 31, 2019
  and December 31, 2018, respectively
      
Series D Convertible Preferred stock, $0.001 par value, 50 shares authorized, 43 issued and
  outstanding, with liquidation preference of $4,320
      
Series G Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized,
  issued and outstanding, with liquidation preference of $5,000
  5   5 
Series I-1 Convertible Preferred stock, $0.001 par value, 2,000 shares authorized, 814 issued and
  outstanding, with liquidation preferences of $814
      
Series I-2 Convertible Preferred stock, $0.001 par value, 4,310 shares authorized,
  issued and outstanding with liquidation preference of $4,310
      
Common stock, $0.001 par value, 120,000,000 shares authorized, 7,533,083 and 6,933,861 shares
  issued and outstanding at March 31, 2019 and December 31, 2018, respectively
  8   7 
Additional paid-in capital  110,742   109,188 
Accumulated deficit  (107,569)  (106,663)
Total stockholders' equity  3,186   2,537 
Total liabilities and stockholders' equity $8,663  $7,796 
         

International Stem Cell Corporation and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)

 Three Months Ended  
 March 31,  
 2019  2018  
Revenues        
Product sales$2,218  $2,633  
Total revenues 2,218   2,633  
Expenses        
Cost of sales 841   825  
Research and development 653   811  
Selling and marketing 692   708  
General and administrative 1,521   1,474  
Total expenses 3,707   3,818  
Loss from operations (1,489)  (1,185) 
Other income (expense)        
Change in fair value of warrant liability 597   355  
Interest expense (14)  (2) 
Miscellaneous income    2  
Total other income (expense), net 583   355  
Loss before provision for income taxes (906)  (830) 
Provision for income taxes     
Net loss$(906) $(830) 
Net loss applicable to common
  stockholders
$(906) $(830) 
Net loss per common share-basic$(0.12) $(0.14) 
Net (loss) per common share-diluted$(0.12) $(0.14) 
Weighted average shares-basic 7,400   6,136  
Weighted average shares-diluted 7,400   6,136  
         

Contacts:

International Stem Cell Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email: ir@intlstemcell.com 

Joe Green
Investor Relations
Edison Inc.
jgreen@edisongroup.com 
+1 (646) 653-7030

isco logo.jpg

NEXT ARTICLE

More From BioPortfolio on "International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...